AtaiBeckley Inc. (ATAI)
Develops experimental psychiatric medicines including psychedelics and novel compounds for depression, anxiety, and cognitive disorders.
$7.18+0.00%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+72.2%
The outlook
ATAI is trading near the top of its 52-week range and above both its 50- and 200-day moving averages, showing upward price momentum. Analyst sentiment is mixed at "Hold," though the average price target sits roughly 34% above the current price. The stock's overall technical positioning appears strong relative to recent history.
What’s behind the score
Analyst consensusHold — 2.6 avg of 8 analysts
Price trendAbove its 50- & 200-day averages
52-week range99% of the way from its 52-week low to high
Price targetAvg target +34% vs current price
Analyst price target
~12-month · 8 analysts$9.59average target+33.5% vs now
Now $7.18
Low $7.45High $16.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$2.66B
52-wk high
$7.22
52-wk low
$3.27
50-day avg
$4.93
200-day avg
$4.38
Trailing P/E
—